
deterior fundament heavi leverag keep
us sell
even teva share intra-day remain sell rate teva
share follow morn earn report co report
better expect ep vs estimate much
upsid driven higher expect copaxon sale
think new ceo kare schultz reorgan plan may lead
long-term recoveri think fundament like deterior
maintain sell rate base lack visibl
bottom co us gener segment mani
gener version mg copaxon could approv
co get underneath outstand debt
co balanc sheet co took goodwil impair
us gener busi anoth major write-down follow last
year goodwil impair occur
lower forecast reflect co guidanc
includ revenu adj ebitda
adj ep lower
total revenu estim co guidanc
ep forecast page detail
ww copaxon sale estimate lower
reflect potenti addit gener entrant
momenta rate recent indic fda
updat complianc statu hospira divis
rate mcpherson facil voluntari action indic vai
expect momenta gain approv shortli partner sandoz
divis novarti nv rate like launch april
base new ebitda estim teva share
trade ev ebitda multipl
valuat rate teva share sell pt arriv
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
lower ep estim reflect signific declin us gener
segment copaxon
reduc revenu forecast adj ep estim
reflect price eros headwind us gener segment combin increas
competit key transit product includ concerta us gener segment experienc
signific pressur revenu yoy revis estim reflect co us gener
segment declin yoy whop percentag point prior estim
cut sever week ago anoth concern believ co face deterior gross profit margin
gener segment drop vs figur sequenti
figur dramat yoy drop gross profit margin troubl recoveri
expect occur add expect drop ww brand copaxon sale due
gener competit think risk factor teva stori even appar
appreci new ceo kare schultz tri lower cost structur end via
dramat restructur plan think challeng co face daunt especi heavili
leverag balanc sheet includ debt end tabl list
estim chang
teva target includ adj ebitda free
copaxon risk remain addit gener competitor enter
teva report stronger expect copaxon sale vs estimate think sale
profit contribut copaxon like drop significantli go forward especi sandoz
gener divis novarti nv rate momenta rate gain entri gener
product expect april last fall buy pt partner natco privat gain fda
approv launch gener version dose copaxon year-end would expect
anoth gener co potenti gain approv enter co file anda includ synthon
privat amneal privat expect merg impax ipxl buy pt dr reddi rdi rate
teva target ww copaxon sale fall gener
copaxon remain teva best sell brand product profit margin
fremanezumab fda approv decis could delay result recent fda
warn letter issu celltrion
morn call ceo kare schultz indic fda action date june
fremanezumab monoclon cgrp antagonist prevent episod chronic migrain recent
warn letter issu celltrion ks equiti could lead potenti approv delay celltrion
key api activ pharmaceut ingredi supplier teva product manag indic delay
month date warn letter issu jan could occur see new
treatment potenti futur blockbust think market crowd compet product
rate rate novarti nv rate also expect enter
teva target leav co littl wiggl room recent
teva focu gener cash flow repay debt total end
remain confid abil oper within debt coven recent amend
appear littl wiggl room given teva ebitda guidanc target
even factor teva pay debt back today co gener ebitda
year co meet credit agreement coven threshold dictat leverag ratio
exceed
current estim teva net debt ebitda ratio stand factor ebitda estim
teva debt matur next year list tabl believ teva
abl meet debt oblig year recent teva receiv allergan settl work
capit disput tie purchas allergan gener busi last year think signific portion
debt matur need refinanc
mid-decemb new ceo kare schultz provid detail restructur plan target reduc net
cost end global workforc cut employe
co also suspend futur dividend payment indic annual bonus would paid
employe manag highlight target get leverag ratio end
equiti rais would occur near-term gener rx segment co plan
discontinu product dont meet new profit benchmark reduc number manufactur
plant reset price certain product categori
teva pharmaceut industri ltd teva earn model gross oper expens pre-tax adj incom net average share dividend prefer adj analysistot earn per compani report btig
btig cover compani mention report
appendix analyst certif import disclosur
